Dachaigh › Melanoma › Massachusetts › Boston
Sgrùdaidhean clionaigeach Melanoma ann an Boston, MA
Tha 26 sgrùdaidhean airson Melanoma a’ lorg phàirtichean aig làraichean ann agus timcheall air Boston (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
A’ fastadhÌre 1/2
- Massachusetts General Hospital, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
A’ fastadhÌre 1/2
- Tufts Medical Center, Boston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
A’ fastadhÌre 2
- Local Institution - 0124, Boston
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
A’ fastadhÌre 1/2
- Massachusetts General Hospital Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
A’ fastadhÌre 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
A’ fastadhÌre 1/2
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Cryoablation+Ipilimumab+Nivolumab in Melanoma
A’ fastadhÌre 2
- Massachusetts General Hospital Cancer Center, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
A’ fastadhÌre 1/2
- Dana-Farber Cancer Institute, Boston
Project: Every Child for Younger Patients With Cancer
A’ fastadhSgrùdadh amharc
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
A’ fastadhÌre 1/2
- Massachusetts General Hospital, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Massachusetts General Hospital Cancer Center, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
A’ fastadhÌre 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
A’ fastadhÌre 1/2
- Call for Information (Investigational Site 0026), Boston
Video Education With Result Dependent dIsclosure
A’ fastadh
- Dana Farber Cancer Institute, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
A’ fastadhÌre 1/2
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
A’ fastadhÌre 1/2
- Massachusetts General Hospital, Boston
Neoadjuvant Darovasertib in Primary Uveal Melanoma
A’ fastadhÌre 3
- Massachusetts General Hospital, Boston
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
A’ fastadhÌre 2/3
- Dana Farber, Boston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
A’ fastadhÌre 2/3
- Massachusetts General Hospital, Boston
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
A’ fastadhÌre 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203 Combined With mRNA-4203
A’ fastadhÌre 1
- Dana Farber Cancer Institute, Boston
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
A’ fastadhÌre 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
A’ fastadhÌre 1/2
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
A’ fastadhÌre 1/2
- Massachusetts General Hospital, Boston
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
A’ fastadhÌre 2
- Dana Farber Cancer Institute, Boston
Sgrùdaidhean Melanoma ann am bailtean eile
- Houston, TX59 sgrùdaidhean
- New York City, NY38 sgrùdaidhean
- Los Angeles, CA34 sgrùdaidhean
- Nashville, TN33 sgrùdaidhean
- Pittsburgh, PA31 sgrùdaidhean
- Philadelphia, PA23 sgrùdaidhean
- San Francisco, CA22 sgrùdaidhean
- Atlanta, GA21 sgrùdaidhean
- Durham, NC21 sgrùdaidhean
- St. Louis, MO21 sgrùdaidhean
- Salt Lake City, UT21 sgrùdaidhean
- Columbus, OH21 sgrùdaidhean
Sgrùdaidhean eile ann an Boston
- Aillse a' bhroilleach111 sgrùdaidhean
- Aillse Sgamhain Neo-chealla-beag90 sgrùdaidhean
- Aillse (gach seòrsa)86 sgrùdaidhean
- Aillse colorectal63 sgrùdaidhean
- Ailse metastatach63 sgrùdaidhean
- Ailseachadh nan Sgamhan62 sgrùdaidhean
- Cancer Ovarian61 sgrùdaidhean
- Aillse Prostata59 sgrùdaidhean
- Depression52 sgrùdaidhean
- Ailse Endometrial50 sgrùdaidhean
- Fàilligeadh a' Chridhe44 sgrùdaidhean
- Leukemia myeloid geur44 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.